Qiagen stock holds steady as analysts see limited upside

Published on 09/09/2026 at 15:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock trades around 42 dollars as of September 9, 2026, close to analysts’ consensus target. Recent guidance for fiscal 2026 points to earnings per share near 2.43 dollars, with a Hold consensus on Qiagen stock.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen N.V. stock (ISIN NL0012169213) is quoted near 42 dollars per share as of September 9, 2026, leaving only a modest gap to the current analyst consensus target price of about 43.93 dollars for the shares.

Analysts keep Qiagen stock at Hold

According to MarketBeat on September 9, 2026, equities analysts currently assign Qiagen a consensus rating of Hold and a consensus target price of 43.93 dollars per share for the stock. This places the implied upside at around 1.6 dollars versus a market level in the low 42-dollar range, indicating that most covering houses see the shares as fairly valued rather than a high-conviction outperform idea.

The same MarketBeat overview notes that analysts as a group expect Qiagen to generate earnings per share of 2.43 dollars in fiscal year 2026, and that the company has set guidance for that year in a range that centers around this figure. According to MarketBeat, Qiagen has communicated fiscal 2026 guidance that points to earnings per share of roughly 2.43 dollars, matching the consensus forecast for the current year. For investors, the key question is whether the company can deliver earnings growth on top of this level in 2027.

Earnings expectations and valuation in focus

On the basis of the current share price near 42 dollars and the fiscal year 2026 earnings-per-share expectation of 2.43 dollars, Qiagen trades at a forward price-earnings multiple of roughly 17.3 times its guided profit for the year. According to MarketBeat, the 2.43-dollar earnings-per-share expectation represents the central value of analyst estimates for the current fiscal year, and any positive surprises relative to this benchmark could be a support for the shares. A miss against this level, in contrast, would increase the likelihood that price targets need to be cut.

Although the latest MarketBeat data set does not break out individual price targets by house, it underscores that the consensus target of 43.93 dollars is not far above the current market quotation. According to MarketBeat, the Hold consensus reflects a mix of Buy, Hold and Sell recommendations but with no strong tilt towards aggressive buying. For retail investors, this combination of a mid-teens earnings multiple and a limited upside to the average target price points to a stock where execution on guidance will likely be more important than multiple expansion over the coming quarters.

Stock price level and trading venue

Qiagen is primarily listed in Amsterdam, with the shares also trading in New York through an ADR structure under the ticker QGEN. In recent trading as of September 9, 2026, the ADR quotation in the United States stands around 42 dollars, only slightly below the 43.93-dollar analyst consensus target and broadly in line with the company’s earnings guidance for fiscal year 2026. Based on the prevailing price level and the guided earnings per share of about 2.43 dollars for the year, the market capitalization implied by the ADR line translates into a valuation that hinges on mid-single-digit earnings growth in subsequent years to justify any significant rerating.

For investors following Qiagen stock, the next major checkpoint will be the company’s upcoming quarterly report and any potential adjustments to its 2026 earnings guidance. With analysts expecting 2.43 dollars earnings per share for fiscal year 2026 and the shares trading at around 42 dollars as of September 9, 2026, the balance between delivered growth and valuation already appears finely tuned, and any deviation from the current trajectory could quickly be reflected in both price targets and the stock price.

Qiagen stock price snapshot

As of the last completed trading day before publication, Qiagen’s ADR on its primary US venue is quoted near 42 dollars, with the closing level on that day only marginally below the 43.93-dollar consensus target price cited by analysts for the shares. At this price, the stock reflects the market’s current assessment of the company’s ability to achieve earnings per share of roughly 2.43 dollars in fiscal year 2026, and leaves limited room for disappointment in the next set of quarterly figures.